Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Patient-reported outcome measures (Proms) in corneal collagen cross-linking: an innovative tool and its correlation to objective measures

Poster Details

First Author: M. Elalfy UNITED KINGDOM

Co Author(s):    H. Hamami   S. Hamada                 

Abstract Details


Currently there are no tools to measure subjective outcomes of corneal collagen crosslinking. PROMS measure patient satisfaction and are an increasingly recommended tool by health organisations. The aim of this study is to design a CXL PROM to correlate quality of life (QOL) with objective visual function parameters.


Queen Victoria Hospital, East Grinstead, UK.


A questionnaire was designed to assess certain psychometric parameters regarding vision related activities and quality of life (QOL) following CXL for progressive keratoconus. The questionnaire was distributed to 26 patients attending follow-up appointments at a minimum of six months after CXL. Objective measures of visual acuity, pachymetry and keratometry were measured on Pentacam. The QOL scores were compared with objective findings to check for correlations.


The disease stabilised in 22 patients and regressed in 4 patients, indicating successful CXL. There was a strong correlation between change in maximum keratometry and higher QOL scores (p=0.041). Patients with improvements in best corrected visual acuity had lower worry scores (p=0.049). Patients with an improvement in mean keratometry had better driving scores (p=0.043). Patients with less advanced disease pre-operatively had better objective results (p=0.017) and a higher QOL (p=0.052).


Objective assessment of CXL efficacy showed that all patients had regression or stability of keratoconus. The treatment was more beneficial in patients with less advanced disease. PROMS is a useful tool to assess QOL in patients who undergo CXL and correlate well with objective tools for measuring CXL outcomes.

Financial Disclosure:


Back to Poster listing